Fulcrum Therapeutics (FULC) Net Cash Flow (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Net Cash Flow for 9 consecutive years, with -$1.9 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Cash Flow fell 559.9% year-over-year to -$1.9 million; the TTM figure through Jun 2026 stood at $5.8 million (up 113.07% YoY), while the FY2025 annual figure was $139.3 million, up 325.3% from the prior year.
• Net Cash Flow improved to -$1.9 million in Q2 2026 per FULC's latest filing, from -$147.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $150.5 million in Q4 2025 and bottomed at -$147.3 million in Q1 2026.
• Historically, Net Cash Flow has averaged $725222.2 across 5 years, with a median of -$1.3 million in 2023.
• Annual changes were most pronounced in 2024 — Net Cash Flow jumped 6189.58% — and 2026, when it sank 818.5%.
• Fulcrum Therapeutics' Net Cash Flow stood at -$55.8 million in 2022, then surged by 91.91% to -$4.5 million in 2023, then plunged by 219.19% to -$14.4 million in 2024, then jumped by 1143.52% to $150.5 million in 2025, then tumbled by 101.27% to -$1.9 million in 2026.
• Business Quant data shows FULC's Net Cash Flow at -$1.9 million in Q2 2026, -$147.3 million in Q1 2026, and $150.5 million in Q4 2025.